AlphaFold predicted structure
MCM4 · P33991

Mean pLDDT
73.6/ 100
Confident
863 residues
Confidence breakdown
- Very high(≥ 90)14%
- Confident(70–90)57%
- Low(50–70)10%
- Very low(< 50)19%
AlphaFold (Jumper et al., 2021) · CC BY 4.0
minichromosome maintenance complex component 4
Annotations refreshed 1 month ago.
Diagnostic Grade (Green)
COVID-19 research
BIALLELIC, autosomal or pseudoautosomalPrimary immunodeficiency or monogenic inflammatory bowel disease
BIALLELIC, autosomal or pseudoautosomalCongenital adrenal hypoplasia
Immunodeficiency with natural-killer cell deficiency and adrenal insufficiency
primary immunodeficiency with natural-killer cell deficiency and adrenal insufficiency
Cytomegalic congenital adrenal hypoplasia
microcephaly
hepatocellular carcinoma
non-small cell lung carcinoma
cancer
breast cancer
breast carcinoma
melanoma
Score is the Open Targets composite evidence score (0-1). Higher = stronger gene-disease association.
DNA replication licensing factor MCM4
Acts as a component of the MCM2-7 complex (MCM complex) which is the replicative helicase essential for 'once per cell cycle' DNA replication initiation and elongation in eukaryotic cells. Core component of CDC45-MCM-GINS (CMG) helicase, the molecular machine that unwinds template DNA during replication, and around which the replisome is built (PubMed:16899510, PubMed:25661590, PubMed:32453425, PubMed:34694004, PubMed:34700328, PubMed:35585232, PubMed:9305914). The active ATPase sites in the MCM2-7 ring are formed through the interaction surfaces of two neighboring subunits such that a critical structure of a conserved arginine finger motif is provided in trans relative to the ATP-binding site of the Walker A box of the adjacent subunit. The six ATPase active sites, however, are likely to contribute differentially to the complex helicase activity (PubMed:16899510, PubMed:25661590, PubMed:32453425, PubMed:9305914)
MCM4 · P33991

Mean pLDDT
73.6/ 100
Confident
863 residues
Confidence breakdown
AlphaFold (Jumper et al., 2021) · CC BY 4.0